Back to Search Start Over

Mechanistic investigation of thermosensitive liposome immunogenicity and understanding the drivers for circulation half-life: A polyethylene glycol versus 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol study.

Authors :
Lokerse, Wouter J.M.
Lazarian, Artur
Kleinhempel, Alisa
Petrini, Matteo
Schwarz, Patricia
Hossann, Martin
Holdt, Lesca M.
Mailänder, Volker
Lindner, Lars H.
Source :
Journal of Controlled Release. May2021, Vol. 333, p1-15. 15p.
Publication Year :
2021

Abstract

Various thermosensitive liposome (TSL) formulations have been described to date and it is currently unclear which are optimal for solid tumor treatment. Sufficient circulation half-life is important and most liposomes obtain this by polyethylene glycol (PEG) surface modification. 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG 2) has been described as a promising alternative which increases TSL circulation half-life and facilitates rapid drug release under mild hyperthermia at 20–30 mol%. The present work describes an investigation of the DPPG 2 -TSL protein corona, blood cell interactions, complement activation in human plasma/blood and hypersensitivity reactions in rats. Furthermore, accelerated blood clearance (ABC) was investigated to obtain a complete assessment of DPPG 2 -TSL interactions with components of the blood and identify drivers for circulation half-life. A higher mol% DPPG 2 increased Apolipoprotein E (ApoE) adsorption and decreased complement activation and granulocyte interaction in vitro. In contrast to PEG-TSL, DPPG 2 -TSL showed no ABC effect. In vivo hypersensitivity assessment by eicosanoid measurements, platelet and lymphocyte counting resembled the results of in vitro complement activation assays although here all DPPG 2 -TSL formulations induced hypersensitive responses upon i.v. administration. Prolonged circulation half-life of DPPG 2 -TSL may be ApoE-induced and the absent ABC effect demonstrates an advantage over PEG-TSL. Low complement activation in human plasma and blood for 20–30 mol% DPPG 2 -TSL presents a unique formulation attribute with the potential to strengthen clinical evaluation. [Display omitted] [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01683659
Volume :
333
Database :
Academic Search Index
Journal :
Journal of Controlled Release
Publication Type :
Academic Journal
Accession number :
150227842
Full Text :
https://doi.org/10.1016/j.jconrel.2021.03.014